Compare MRK & WFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRK | WFC |
|---|---|---|
| Founded | 2000 | 1852 |
| Country | United States | United States |
| Employees | N/A | 200999 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 268.7B | 224.7B |
| IPO Year | 1994 | N/A |
| Metric | MRK | WFC |
|---|---|---|
| Price | $114.57 | $83.11 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 18 |
| Target Price | ★ $125.59 | $96.59 |
| AVG Volume (30 Days) | 8.3M | ★ 11.7M |
| Earning Date | 04-30-2026 | 04-14-2026 |
| Dividend Yield | ★ 3.06% | 2.21% |
| EPS Growth | ★ 8.01 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $65,011,000,000.00 | N/A |
| Revenue This Year | $3.61 | $11.08 |
| Revenue Next Year | $5.41 | $4.76 |
| P/E Ratio | ★ N/A | $14.15 |
| Revenue Growth | ★ 1.31 | N/A |
| 52 Week Low | $76.66 | $72.78 |
| 52 Week High | $125.14 | $97.76 |
| Indicator | MRK | WFC |
|---|---|---|
| Relative Strength Index (RSI) | 43.47 | 59.19 |
| Support Level | $112.96 | $78.04 |
| Resistance Level | $123.93 | $87.59 |
| Average True Range (ATR) | 2.99 | 1.95 |
| MACD | -0.60 | 0.46 |
| Stochastic Oscillator | 21.57 | 61.77 |
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.